PGR and neoplasm: The proportion of PD-L1 expression in TCs and ICs was determined according to the following clinicopathological variables: age, tumor size, lymph node status, hormone receptor (ER, PR, HER2) status, Ki-67 index, and molecular subtypes (luminal A and B, HER2-positive, and triple-negative).